Impact of Metabolomics Technologies on the Assessment of Peritoneal Membrane Profiles in Peritoneal Dialysis Patients: A Systematic Review.

Antonia Kondou,Anna Taparkou,Olga Begou,Eleftherios Panteris,Helen Gika,Nikoleta Printza,John Dotis,Vasiliki Karava

doi:10.3390/metabo12020145

Antonia Kondou, Anna Taparkou + Show 6 more

Open Access

https://doi.org/10.3390/metabo12020145

Copy DOI

Journal: Metabolites	Publication Date: Feb 4, 2022
Citations: 3	License type: CC BY 4.0

Affiliation: Aristotle University of Thessaloniki

Abstract

Peritoneal dialysis (PD) is an effective and frequent dialysis modality in adults, particularly preferred in infants and young children with end-stage renal disease (ESRD). Long-term exposure of the peritoneal membrane to dialysis solutions results in severe morphologic and functional alterations. Peritoneal dialysis effluent biomarkers are based on omics technologies, which could predict the onset or confirm the diagnosis of peritoneal membrane dysfunction, would allow the development of accurate early prognostic tools and, potentially, the identification of future therapeutic targets. The purpose of our study was to critically review the literature on the impact and the effectiveness of metabolomics technologies in peritoneal health. The main search was performed in electronic databases (PubMed/MEDLINE, Embase and Cochrane Central Register of Controlled Trials) from inception to December 2020, using various combinations of Medical Subject Headings (MeSH). The main search highlighted nine studies, of which seven were evaluated in detail. Metabolomics technologies may provide significant input in the recognition of peritoneal membrane dysfunction in PD patients and provide evidence of early intervention strategies that could protect peritoneum health and function.

Highlights

Peritoneal dialysis (PD) is a safe and common treatment modality in adults and the preferred mode of dialysis in children with end-stage kidney disease (ESKD) [1]
Peritoneal dialysis effluent biomarkers are based on omics technologies, which could predict the onset or confirm the diagnosis of peritoneal membrane dysfunction, would allow the development of accurate early prognostic tools and, potentially, the identification of future therapeutic targets
The main search was performed in electronic databases (PubMed/MEDLINE, Embase and Cochrane Central Register of Controlled Trials) from inception to December 2020, using various combinations of Medical Subject Headings (MeSH)

Summary

Introduction

Peritoneal dialysis (PD) is a safe and common treatment modality in adults and the preferred mode of dialysis in children with end-stage kidney disease (ESKD) [1]. The method is based on the peritoneal membrane, which features as a semi-permeable barrier for ultrafiltration and diffusion [2]. Long-term exposure of the peritoneal membrane to PD solutions, multiple episodes of PD-related peritonitis and high glucose load PD solutions eventually result in peritoneal morphological and functional alterations, which may cause peritoneal membrane fibrosis, with the clinical outcome of loss of peritoneal ultrafiltration capacity [3]. Diagnosis is usually made in advanced stages of the disease by laparotomy or positron emission tomographic imaging [6]. The pathogenesis of peritoneal membrane dysfunction and progression to EPS remains poorly understood. The mostly involved mechanisms include peritoneal inflammation and angiogenesis, as well as mesenchymal conversion of mesothelial cells, which is called the mesothelial to mesenchymal transition (MMT) [9]

Objectives

Results

Discussion

Conclusion